Ranolazine
- Generic Name
- Ranolazine
- Brand Names
- Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H33N3O4
- CAS Number
- 95635-55-5
- Unique Ingredient Identifier
- A6IEZ5M406
- Background
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
- Indication
Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence. Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.
- Associated Conditions
- Chronic Angina, Ventricular Arrhythmia
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
- Conditions
- Coronary Artery DiseaseAngina Pectoris
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2651
- Registration Number
- NCT01442038
- Locations
- 🇺🇸
Tallahassee Research Institute, Tallahassee, Florida, United States
🇺🇸Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸Veterans Administration Medical Center, Pittsburgh, Pennsylvania, United States
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
- Conditions
- End-stage Renal DiseaseCardiovascular Disease
- Interventions
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 17
- Registration Number
- NCT01435174
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
- Conditions
- Angina PectorisType 2 Diabetes MellitusCoronary Artery Disease
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 949
- Registration Number
- NCT01425359
- Locations
- 🇷🇺
State Institution of Healthcare Perm Regional Hospital for War Veterans, Perm, Russian Federation
🇺🇸Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
🇺🇸Med-Tech Research, Houston, Texas, United States
Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
- Conditions
- Heart; Dysfunction Postoperative, Cardiac Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- William Beaumont Hospitals
- Target Recruit Count
- 15
- Registration Number
- NCT01352416
- Locations
- 🇺🇸
William Beaumont Hospital, Troy, Michigan, United States
Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 10
- Registration Number
- NCT01349491
- Locations
- 🇺🇸
OU Medical Center, Oklahoma City, Oklahoma, United States
🇺🇸Oklahoma City VA Medical Center, Oklahoma City, Oklahoma, United States
Ranolazine in Ischemic Cardiomyopathy
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Midwest Cardiovascular Research Foundation
- Target Recruit Count
- 28
- Registration Number
- NCT01345188
- Locations
- 🇺🇸
Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States
Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia
- Conditions
- Microvascular Coronary Dysfunction (MCD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-04-26
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 142
- Registration Number
- NCT01342029
- Locations
- 🇺🇸
127 S. San Vicente Blvd, Suite A9303, Los Angeles, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Angina PectorisCoronary Artery DiseaseType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01334203
Ranolazine, Ethnicity and the Metabolic Syndrome
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Atlanta Heart Specialists, LLC
- Target Recruit Count
- 160
- Registration Number
- NCT01304095
- Locations
- 🇺🇸
Atlanta Heart Specialist, LLC, Cumming, Georgia, United States
🇺🇸Atlanta Heart Specialists, LLC, Tucker, Georgia, United States
Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
- Conditions
- Myocardial Perfusion ImagingMyocardial Ischemia
- Interventions
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 81
- Registration Number
- NCT01221272
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇨🇦Chum Hotel Dieu, Montreal, Quebec, Canada
🇫🇮Turku University Hospital, Turku, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.